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Background. There is substantial variation in the reported treatment outcomes for adult tuberculous meningitis (TBM). Data 
on survival and neurological disability by continent and HIV serostatus are scarce.
Methods. We performed a systematic review and meta-analysis to characterize treatment outcomes for adult TBM. Following a 
systematic literature search (MEDLINE and EMBASE), studies underwent duplicate screening by independent reviewers in 2 stages 
to assess eligibility for inclusion. Two independent reviewers extracted data from included studies. We employed a random effects 
model for all meta-analyses. We evaluated heterogeneity by the I2 statistic.
Results. We assessed 2197 records for eligibility; 39 primary research articles met our inclusion criteria, reporting on treatment 
outcomes for 5752 adults with TBM. The commonest reported outcome measure was 6-month mortality. Pooled 6-month mortality 
was 24% and showed significant heterogeneity (I2 > 95%; P < .01). Mortality ranged from 2% to 67% in Asian studies and from 23% 
to 80% in Sub-Saharan African studies. Mortality was significantly worse in HIV-positive adults at 57% (95% CI, 48%–67%), com-
pared with 16% (95% CI, 10%–24%) in HIV-negative adults (P < .01). Physical disability was reported in 32% (95% CI, 22%–43%) of 
adult TBM survivors. There was considerable heterogeneity between studies in all meta-analyses, with I2 statistics consistently >50%.
Conclusions. Mortality in adult TBM is high and varies considerably by continent and HIV status. The highest mortality is 
among HIV-positive adults in Sub-Saharan Africa. Standardized reporting of treatment outcomes will be essential to improve future 
data quality and increase potential for data sharing, meta-analyses, and facilitating multicenter tuberculosis research to improve 
outcomes.
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In 2018, 10 million cases of tuberculosis were reported globally 
[1]; tuberculous meningitis accounts for 1%–5% of these cases 
[2]. Tuberculous meningitis is the most severe form of tubercu-
losis and is responsible for a considerable burden of neurolog-
ical sequelae and mortality; a systematic review of treatment 
outcomes in 1636 children with tuberculous meningitis esti-
mated a mortality rate of 19.3% [3]. There is considerable varia-
tion in the reported outcomes for adult tuberculous meningitis 
across available studies; the reasons for this remain unclear. 
Two recent systematic reviews of adult tuberculous meningitis 
outcomes reported substantial heterogeneity in mortality and 
the proportion of deaths among those diagnosed with TBM, 
with pooled estimates of 22.8% and 24.7% [4, 5]. However, 
neither review attempted to explain the variation in treatment 
outcomes by stratifying studies by HIV status and geographical 
location. In addition, Wen and colleagues excluded all investiga-
tional treatment studies, effectively excluding major treatment 
randomized controlled trials (RCTs) investigating regimens 
that have now become the standard of care (eg, adjunctive ster-
oids and delayed antiretroviral therapy [ART] for those with 
HIV-associated tuberculous meningitis). Furthermore, there 
is a paucity of data in recent meta-analyses on drug resistance 
rates, treatment regimens, and steroid use. HIV co-infection 
has been shown to be a risk factor for death (hazard ratio, 2.5; 
95% CI, 1.9–3.4) in Vietnamese adults with tuberculous menin-
gitis [6], but this remains to be explored systematically in other 
regions [7–9]. Neurological disability in adult tuberculous men-
ingitis survivors has not been studied in detail in meta-analyses. 
In 2 recent systematic reviews, the prevalence of disability in 
adult tuberculous meningitis survivors varied between 29% and 
50% [4, 5]. However, neither review provided data on the nature 
and severity of neurological sequelae in tuberculous meningitis 
survivors.
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We performed a systematic review and meta-analysis to char-
acterize treatment outcomes, namely all-cause mortality and 
neurological sequelae, for adult tuberculous meningitis across a 
range of epidemiological settings. We endeavored to perform a 
definitive review by including the best quality data available and 
performing a robust quality assessment of the studies included.
METHODS
Literature Search Strategy
This review followed the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) statement 
for the reporting of systematic reviews and meta-analyses [10]. 
A systematic electronic search was conducted using MEDLINE 
and EMBASE with the aim of identifying all studies reporting 
treatment outcomes in adult tuberculous meningitis from 1988 
to the present. This time period corresponds to the WHO rec-
ommendation of standard quadruple therapy for the treatment 
of tuberculosis [1]. Controlled and natural language terms iden-
tified key search concepts such as “tuberculosis,” “meningitis,” 
“mortality,” “complications,” and “outcome.” The full search 
strategies are presented in Supplementary Appendix A. Searches 
were conducted on July 9, 2018.
Study Selection
A 2-stage sifting process was employed: (1) at title and abstract 
and (2) at full-text level according to eligibility criteria as de-
tailed below. Sifting was performed in duplicate independently 
by 2 reviewers, and any unresolved disagreements were re-
solved by a third independent reviewer. Reference and citation 
checking were conducted for included articles.
Studies were eligible for inclusion if they (i) included adults 
(aged ≥15 years) with confirmed or suspected TB meningitis; 
(ii) utilized diagnostic criteria to systematically evaluate pa-
tients for tuberculous meningitis; (iii) reported on at least 1 
of the following outcome measures: neurological sequelae, 
in-hospital mortality, mortality at the end of follow-up; (iv) 
employed any of the following study designs: consecutive case 
series, case–control study, cohort study, randomized controlled 
study, systematic review, or meta-analysis.
The following exclusion criteria were applied: (i) studies with 
<10 participants; (ii) studies limited to specific complications or 
comorbidities (eg, hydrocephalus, tuberculoma, or surgical inter-
vention); (iii) studies not providing at least a backbone of standard 
fixed-dose combination antituberculous therapy; (iv) studies not 
specifying treatment given; (v) studies published before 1988; (vi) 
studies not written in English; (vii) any systematic review super-
seded by an updated systematic review; (viii) narrative reviews not 
adding new data or new analysis of data to existing knowledge.
Data Extraction and Data Synthesis
Two authors independently extracted data on study character-
istics, recruitment populations, and treatment outcomes from 
eligible studies using a standardized, piloted electronic data 
capture database (REDCap, Vanderbilt University, Nashville, 
TN, USA). We captured data on geographical region, number 
of HIV-positive participants, British Medical Research Council 
(MRC) tuberculous meningitis grade at presentation, treat-
ment regimens utilized, use of corticosteroids, and outcomes 
reported at specified time points for each study. Any unresolved 
disagreements in extraction were resolved by a third inde-
pendent reviewer.
We used each study’s definition of neurological sequelae as 
reported in the study. For articles that utilized the modified 
Rankin Scale or the Barthel index, “disability” was defined as 
“any disability that impeded the patient’s ability to carry out 
tasks they once performed.” This is was represented as a score of 
>2 on the Modified Rankin Scale or <80 on the Barthel Index.
For systematic reviews, individual study-level data were not 
extracted or analyzed; only the summary estimates were re-
corded for comparison, and citation checking was performed 
to ensure all relevant source manuscripts had been identified.
Data Analysis
We used the proportion of all-cause deaths and neurological 
sequelae within each study to define outcomes of tuberculous 
meningitis for the meta-analyses. As such, all meta-analyses 
used random effects models and employed the DerSimonian 
and Laird method on Freeman-Tukey transformed propor-
tions, which is the established approach for this type of analysis 
[11–13]. We graphically displayed data in forest plots, which 
display point estimates of tuberculous meningitis outcomes in 
each study, with 95% confidence intervals. We generated pooled 
effect estimates by inverse variance–weighting each individual 
point estimate, such that the estimates with lower variances con-
tributed more to the pooled estimate [13]. The overall pooled 
estiamte for mortality was stratified by follow-up outcome re-
porting time. Interstudy and subgroup heterogeneity were as-
sessed with the I2 statistic. All analyses were conducted in Stata, 
version 15.1 (StataCorp, College Station, TX, USA), with the 
“metaprop” command [14].
Quality Assessment
The 39 articles included in the meta-analysis were assessed 
for study quality using the Downs and Black tool, a 27-item 
quality assessment checklist [15]. Each study was scored on 
a 32-point scale for items that examined quality of reporting, 
external validity, internal validity (bias and confounding), and 
study power. Study power was estimated according to sample 
size methodology. Studies were scored as follows; 0 if no sample 
size calculation was made or reported in the manuscript (given 
for observational studies); 3 if a power calculation was done 
but there were insufficient numbers of patients recruited; 5 
if the power calculation was done and sufficiently powered. 
Systematic reviews meeting the inclusion criteria were not 
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assessed for risk of bias. As treatment outcomes were of interest 
in these analyses and not treatment or intervention efficacy, we 
included all studies regardless of quality assessment score.
Role of Funding Source
The Fogarty International Center of the National Institutes of 
Health provided funding fellowship support to the lead au-
thor of the study. The funders had no role in the study design, 
data collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to all the 
data in the study and had final responsibility for the decision to 
submit for publication.
RESULTS
Search Results, Studies, and Participants Included
Our searches yielded 2562 reports. After removal of duplicates 
(n = 365), 2197 studies underwent title and abstract screening, 
and 264 full texts were reviewed (Figure 1). Thirty-nine studies 
met our eligibility criteria for inclusion and analysis (Table  1). 
These 39 studies were published between 1995 and 2018; 10 
(26%) were case series, 21 (54%) were cohort studies, and 8 
(21%) were randomized controlled trials. Studies arose from 18 
countries, including a range of epidemiological settings; 24 (62%) 
were from high–TB burden settings, and 15 (38%) were from 
low–TB burden settings. A total of 26 (67%) studies were con-
ducted in Asia, and 5 (13%), 5 (13%), and 2 (5%) were conducted 
in Europe, Africa, and the Americas, respectively (Figure  2). 
Study quality scores ranged from 8 to 32, with a score of 32 
indicating the highest quality. The median quality score for in-
cluded articles (interquartile range [IQR]) was 18 (15–20). Our 
meta-analysis includes reported treatment outcomes for 5752 
adults with tuberculous meningitis. Participant age ranged from 
15 to 88 years. Seven studies included 1078 HIV-positive patients: 
302 (28%) from Africa and 776 (72%) from Asia. MRC tubercu-
lous meningitis grade was reported in 29 studies, in which 28% 
(1354/4761) of participants presented with MRC grade I disease, 
48% (2302/4761) with grade II, and 20% (967/4761) with grade 
III. A total of 37 studies (n = 5623 participants) reported the clas-
sification or uniform case definition of enrolled participants. Of 
Full-text articles excluded (n = 225)
Nontuberculous meningitis (n = 13)
No systematic diagnostic criteria for diagnosing tuberculous meningitis (n = 25)
Did not report at least 1 outcome of interest (n = 9)
Ineligible study type or study type not specified (n = 10)
Fewer than 10 study participants (n = 3)
Non-English articles (n = 27)
Study conducted before 1988 (n = 8)
Study sample limited to patients with specific complications or comorbidities (n = 5)
Full text unable to be located (n = 27)
No disaggregated tuberculous meningitis data (n = 6)
No disaggregated adult data (n = 58)
No specified treatment drugs, doses, and duration (n = 30)
Narrative reviews or new analysis of existing data (n = 2)























Figure 1. Flow diagram of the study selection process.
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those, 40% (2243/5623) were microbiologically confirmed tuber-
culous meningitis and 49% (2741/5623) were suspected tuber-
culous meningitis, the latter of which included 21% (1013/5623) 
with probable tuberculous meningitis and 12% (663/5623) with 
possible tuberculous meningitis according to the uniform case 
definition [16]. Only 12 studies reported on drug resistance rates; 
10 studies included patients with multidrug-resistant tubercu-
losis (n = 49), and 12 studies included patients with mono-drug-
resistant tuberculosis, of which 10 studies included isoniazid 
resistance (n = 112 participants), 6 studies included rifampin re-
sistance (n = 12 participants), and 1 study included streptomycin 
resistance (n = 1 participant).
The most common treatment regimen was standard 4-drug 
therapy of rifampicin, isoniazid, pyrazinamide, and etham-
butol (RHZE) with no additional antituberculous drugs 
(n  =  17 studies). Seven studies used streptomycin in ad-
dition to or in replacement for ethambutol (Table  1). The 
median treatment duration (IQR) was 9 (9–12) months. 
Corticosteroids were given to all patients in 19 studies and to 
some participants in 10 studies (Table 1). Treatment outcomes 
by corticosteroid use were examined in a meta-analysis with 
included studies, but this was not the aim or design of our 
meta-analysis, and a significant amount of heterogeneity in 
mortality between studies was unexplained (Supplementary 
Appendix B). A  Cochrane meta-analysis on corticosteroid 
use in TBM was published in 2016 [57].
Mortality Assessment and Outcomes
A wide range of mortality end points were reported: 15% (6/39) 
studies reported 1-month mortality, 5% (2/39) studies reported 
2-month mortality, 8% (3/39) studies reported 3-month mor-
tality, 18% (7/39) studies reported 6-month mortality, 13% 
(5/39) studies reported 12-month mortality, and 2% (1/39) 
reported 5-year mortality. Other reported outcomes included 
in-hospital mortality (n = 6 studies) and median time to death 
(n = 4 studies). In the 6 studies that reported on “in-hospital 
mortality,” only 1 study reported on the length of hospitaliza-
tion, which ranged from 4 to 10 days until death or discharge. 
Five studies did not define “in-hospital mortality” in terms of 
time frame.
To investigate time-specific mortality, articles were 
grouped by follow-up outcome reporting time point. Articles 
that reported outcomes ≤3  months were included in the 
3-month reporting category to summarize “early” mortality. 
Articles that reported outcomes >3 months to 6 months were 
included in the 6-month reporting category. Articles that re-
ported outcomes >6 months were included in the 12-month 
reporting category. Of articles reporting outcomes at 3, 6, and 
12 months, pooled mortality was 23% (95% CI, 14%–35%), 
23% (95% CI, 14%–33%), and 25% (95% CI, 17%–33%), re-
spectively (Figure  3). There was significant heterogeneity 
(I2  =  95%; P  <  .01) for all outcome reporting time points. 
There was no marked heterogeneity in mortality between 
outcome reporting time points (P = .60), but it was included 
in the pooled analysis, resulting in a pooled mortality of 24% 
(95% CI, 19%–29%).
Mortality End Points by HIV Status
Seven studies reported mortality for HIV-positive adults. For 
HIV-positive adults, pooled mortality was 57% (95% CI, 48%–
67%), compared with 16% (95% CI, 10%–24%) in HIV-negative 
adults (Figure 4). HIV status explained a significant amount of 
the observed heterogeneity in tuberculous meningitis mortality 
(P < .01).























Figure 2. Tuberculous meningitis mortality by country. Pooled mortality for tuberculous meningitis by country. Mortality for countries with only 1 study reflect the reported 
mortality for that 1 study.
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Figure 3. Tuberculous meningitis mortality by outcome reporting time point. Forest plots depicting mortality due to tuberculous meningitis at 3, 6, and 12 months. One study 
was excluded because the outcome time point was not reported.
Mortality End Points by Geographical Region
Most studies reporting on tuberculous meningitis mortality 
were conducted in India and the Asian continent (n = 27; 70%), 
where pooled mortality ranged from 2% to 67% (Figure  2). 
The countries reporting the highest tuberculous meningitis 
mortality were located in Sub-Saharan Africa, where mortality 
ranged from 23% to 80%. Continent (Africa vs Asia) explained 
a significant amount of the observed heterogeneity in tubercu-
lous meningitis mortality (P = .02).
Temporal Variation in Mortality End Points
To investigate changes in tuberculous meningitis treatment out-
comes over time, we conducted a temporal analysis in which 
individual studies were allocated to 1 of 5 time periods and strat-
ified analyses were conducted. Time periods were subdivided 
into 5-year windows from 1995 onwards, and pooled mortality 
was analyzed within each time window. The highest pooled 
mortality was 31% (95% CI, 14%–51%) in articles published 
from 2006 to 2010, though there was no significant variation 
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by time window (Supplementary Appendix C). In earlier time 
periods, heterogeneity in survival was greatest, and heteroge-
neity appears to have declined in more recent time periods.
Neurological Disability
Functional outcomes among survivors was a prespecified end 
point in 24 studies; 10 studies reported on functional outcomes 
using the Modified Rankin Scale score (n = 6) or the Barthel 
Index (n = 5), 10 studies reported on neurocognitive disability 
without using a specified scale or measurement tool, and 5 
studies reported using “clinical assessments.”
The timing and method of neurological assessments varied 
between studies; the most commonly used outcome assess-
ment was physical disability conducted at the end of follow-up. 
In this analysis, participants were considered disabled if there 
was any indication of functional disability as reported by the 
Modified Rankin Scale or Barthel Index. Of the studies utilizing 
the Modified Rankin Scale, the pooled proportion of patients ex-
periencing some level of physical disability was 26% (95% CI, 
18%–35%), with considerable heterogeneity (Supplementary 
Appendix D). Of the studies using the Barthel Index, the pro-
portion of patients experiencing some level of physical disability 
was 32% (95% CI, 22%–43%), with only moderate heterogeneity.
DISCUSSION
In this rigorous systemic review and meta-analysis, we reviewed 
treatment outcomes for >6000 adults with tuberculous menin-
gitis, and our data clearly demonstrate that the mortality and 
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Figure 4. Tuberculous meningitis mortality by HIV status. Forest plot depicting mortality due to tuberculous meningitis stratified by HIV status. HIV status explains a signif-
icant amount of the heterogeneity in tuberculous meningitis mortality (P < .01).
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neurological sequelae associated with tuberculous meningitis 
remain unacceptably high. Although there was significant het-
erogeneity between studies (I2 > 95%), the overall risk of death 
was 23% at 3 months and 25% at 12 months. In patients who did 
survive, neurological sequelae were common, affecting nearly 
one-third of all patients. Furthermore, our temporal analysis 
of treatment outcomes indicates that prognosis has improved 
little over time. Our results are in concordance with 2 recently 
published systematic reviews, which reported overall morality 
associated with adult tuberculous meningitis to be 23% and 
25% and risk of neurological sequelae to be 29% and 50%, re-
spectively. Our study expands on the current literature through 
subgroup meta-analyses to evaluate differential treatment out-
comes by HIV status and geographical region.
We have demonstrated that patients with HIV-associated tu-
berculous meningitis have 3-fold higher mortality compared 
with HIV-negative cohorts; mortality in HIV-negative cohorts 
ranged between 10% and 24%, compared with 48%–67% in 
HIV-positive cohorts (P  <  .01). Pathogenesis research is ur-
gently needed to investigate the disproportionate mortality as-
sociated with HIV co-infection in tuberculous meningitis and 
to identify potential interventions or preventative measures.
Second, our data demonstrate that despite adoption of 
standardized treatment regimens for tuberculous meningitis, 
considerable global disparities in treatment outcomes exist. 
Pathogenesis work has shown that even within a Vietnamese 
population, a single genetic polymorphism significantly impacts 
corticosteroid responsiveness and survival from TBM [58]. The 
extent of the heterogeneity observed in this meta-analysis raises 
the possibility that genetic or other latent factors may con-
tribute to outcome, and the current one-size-fits all approach to 
treatment may be effective in some individuals/populations and 
less effective in others. Our subgroup meta-analyses indicate 
that patients in the African continent have a higher mortality 
compared with all other continents. This may in part be ex-
plained by the higher co-prevalence of HIV. However, given the 
considerable resource limitations including a lack of intensive 
care facilities typical of many settings in Sub-Saharan Africa, it 
is likely that the management of commonly encountered com-
plications of tuberculous meningitis including hyponatremia, 
raised intracranial pressure, hydrocephalus, stroke, and noso-
comial infections is suboptimal. Further research is needed to 
determine the attributable mortality due to a lack of supportive 
or critical care in Sub-Saharan Africa. Our systematic literature 
review highlights the historical paucity of clinical studies pub-
lished from this continent. In order to address the devastatingly 
poor outcomes from HIV-associated meningitis, particularly 
for those in Sub-Saharan Africa, we need to design, fund, and 
deliver more clinical research.
Our meta-analyses of follow-up time-specific mortality at 3, 
6, and 12 months highlight that >90% of tuberculous menin-
gitis deaths occur in the first 3  months. This may justify that 
3-month mortality is a reasonable RCT end point, potentially 
making study trial follow-up shorter and cheaper, thereby ac-
celerating research outputs. However, the considerable heter-
ogeneity found in these analyses, as well as inconsistencies in 
reporting outcomes, indicates that further evidence is needed 
to justify a 3-month clinical trial end point. Clinical studies to 
identify drivers of early mortality in tuberculous meningitis 
may inform the design of treatment intensification strategies 
and other adjunctive interventions.
Concerningly, our results demonstrate that minimal im-
provements in survival have been made over time. There are 
a number of temporal factors that may have affected outcomes 
in certain time periods including the height of the HIV epi-
demic in the 1990–2005 period: ART rollout in the 1995–2010 
window, the increasing availability of more rapid diagnostics in 
the form of the Xpert MTB/Rif assay in the 2010–2020 window 
facilitating the diagnosis of tuberculous meningitis where it was 
previously unconfirmed, and, lastly, gradually increasing rates 
of antituberculous drug resistance worldwide. Reporting bias, 
which may have varied over time, must also be considered.
Our analysis has several limitations. First, although we only 
included studies that employed a prespecified diagnostic crite-
rion for tuberculous meningitis, there was considerable varia-
tion in the quality of diagnostic criteria used, and diagnostics 
have changed over time. We chose not to restrict diagnostic 
criteria to microbiologically confirmed tuberculous menin-
gitis because doing so would have restricted our meta-analysis 
to 40% (n = 2243) of adults, and furthermore we wanted our 
results to be generalizable to real-world clinical settings where 
confirmation rates are often only moderate. We do, however, 
recognize that misclassification of undifferentiated meningitis 
cases as tuberculous meningitis is common, especially when 
left to physician discretion, as may have been the case in some 
of the patients included in our meta-analysis, which would un-
dermine the accuracy of our outcome estimates. Second, in the 
spirit of generalizability, we chose to include case series, which 
are primarily descriptive and not wholly representative of the 
populations they are drawn from. Although this may have 
posed some unmeasurable bias, we believe that this would not 
have substantially impacted our results, as mortality and neu-
rological sequelae, our outcomes of interest, would not have 
measured differently or changed based on study design. Third, 
the specific antituberculous regimen utilized and drug resist-
ance rates within the cohorts were inconsistently reported in 
studies; therefore, we were unable to conduct stratified meta-
analyses based on drug resistance patterns. The International 
Tuberculous Meningitis Research Consortium paper on stand-
ardized methods for enhanced quality and comparability of 
tuberculous meningitis studies specifies that it is essential to 
document the dose, route of administration, and duration of all 
antituberculosis drugs used in tuberculous meningitis studies 
[59]. There remain several outstanding questions concerning 
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the optimal treatment of tuberculous meningitis, and therefore 
to facilitate cross-study comparisons and interrogate differences 
in study outcomes, basic information about the treatment pro-
vided is essential.
Finally, there was a considerable lack of standardization of 
reporting on treatment outcomes. This was particularly marked 
with respect to reporting of neurological sequelae; first, neu-
rological sequalae were rarely reported (only 10/39 [26%] 
studies including any data on neurological sequalae), the tools 
used were inconsistent (9 tools in total), and the time points 
for assessment were rarely reported. This inconsistent reporting 
hampered comparison of data across studies. Given the im-
portance of neurological disability in tuberculous meningitis 
and the importance of developing a standardized evidence 
base against which to assess new treatments, the International 
Tuberculous Meningitis Research Consortium recommends 
that the Modified Rankin Score be used as the first-line tool, 
which should be recorded at 12 months from antituberculosis 
treatment initiation in all adults [59]. We support this recom-
mendation, and in addition we would suggest that mortality be 
routinely reported on at 3, 6, and 12 months, if possible, to im-
prove study comparability.
The strengths of this work include its size, with 39 individual 
studies included from Asia, Africa, Europe, and the Americas, 
making our estimates broadly generalizable to a range of set-
tings. Our systematic review is larger than 2 previously pub-
lished systematic reviews of adult tuberculous meningitis [4, 
5]. In comparison to Wen et al. [4], we decided to include ran-
domized controlled trials in our systematic review, which en-
abled us to include the highest quality of trial evidence, and we 
also reported drug resistance rates within each included study. 
In comparison to Wang et al. [5], we ascertained variation in 
treatment outcomes geographically and reported on the nature 
and severity of reported neurological sequelae. Overall, we as-
sessed a wide range of covariates to investigate the heteroge-
neity in treatment outcomes observed. To our knowledge, this 
is the most extensive critical appraisal of tuberculous meningitis 
outcomes to date.
In conclusion, adult tuberculous meningitis is associated 
with considerable neurological morbidity and mortality and 
remains a major challenge in TB-endemic regions. The worst 
outcomes are observed by those with HIV co-infection in 
Sub-Saharan Africa, where risk of death is 3-fold higher. Our 
study was limited by suboptimal reporting on diagnostic cri-
teria utilized, drug resistance rates, and details of treatment 
regimens used, as well as highly variable outcome reporting. 
Adoption of standardized reporting systems across tubercu-
lous meningitis studies would not only facilitate cross-study 
comparisons, but would also improve the quality of research 
outputs overall and support collaborative research across cen-
ters with an aim of improving tuberculous meningitis out-
comes globally.
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